SLC5A2 and diabetes mellitus: We have highlighted DM as a risk factor for declining eGFR in our patient group and quantified the substantial increased mortality that accompanies this, our data therefore adds evidence for the potential benefits from SGLT2 inhibitor treatment in patients with HFrEF.